Open AccessInterleukin‐17 in acute myeloid leukemia
Author(s) -
Wróbel T.,
Mazur G.,
Jazwiec Bozena,
Kuliczkowski K.
Publication year - 2003
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2003.tb00250.x
Subject(s) - angiogenesis , myeloid leukemia , medicine , proinflammatory cytokine , myeloid , leukemia , immunology , cytokine , interleukin 17 , interleukin , chemotherapy , cancer research , inflammation
There are several reports that angiogenesis plays important roles in hematological malignancies including acute myeloid leukemia (AML). Human interleukin‐17 (IL‐17) is a proinflammatory cytokine produced by activated CD4 T cells. IL‐17 plays a potential role in T cell mediated angiogenesis. The role of IL‐17 in pathologic angiogenesis has not been evaluated yet. The aim of the study was to determine plasma level of IL‐17 in patients with AML. IL‐17 levels were measured by ELISA in plasma samples taken from 68 adult patients with AML before chemotherapy was administered. In addition 20 out of 68 patients were reanalysed after achieving complete remission (CR). Ten samples from healthy volunteers were evaluated as the control. In this study we have demonstrated that serum level of IL‐17 is not elevated in AML patients. These results suggest that angiogenesis in AML is not mediated by CD4 T cells. To our knowledge this is the first report about IL‐17 serum level in acute leukemias. We are currently evaluating IL‐17 levels in others haematological malignancies.